Novo Nordisk A/S

NVO

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
March 25, 2025

Days Left:
48

calendar

Novo Nordisk A/S Form












Stock Fraud Law Center does not share your information with others. There is no cost or obligation for you to submit.

Allegations

According to the complaint, on December 20, 2024, Novo issued a press release announcing the below-expected results of their “REDEFINE 1” trial, “a 68-week efficacy and safety trial investigating subcutaneous CagriSema.” The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo’s targeted expectation of at least 25% weight loss. The press release further indicated that participant patients were permitted to modify their own dosage during the trial and, as a result, only 57.3% of patients treated with CagriSema were on the highest dosage contemplated by the study. Following this news, Novo’s stock price fell by $18.44 per share to close at $85.00 per share.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Novo purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Novo during the relevant time frame, you have until March 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
SUI Sun Communities, Inc. February 10, 2025 Join
SAVA Cassava Sciences, Inc. February 10, 2025 Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join
PCRX Pacira BioSciences, Inc. March 14, 2025 Join
NVO Novo Nordisk A/S March 25, 2025 Join
GO Grocery Outlet Holding Corp. March 31, 2025 Join
NEM Newmont Corporation April 01, 2025 Join